Hypoxia and Inflammatory Injury in Human Renovascular Hypertension

Overview

Current treatments for ARAS based on restoring blood flow alone have been unsuccessful at recovering kidney function. For this reason we are studying a stem cell product called "mesenchymal stem cells" or MSC. Mesenchymal stem cells (MSC) are grown from a person's own fat tissue (obtained as a fat biopsy) and infused back into the patient's own kidney. This study is also being done to determine if the MSC infusion prior to percutaneous transluminal renal angioplasty with stenting (PTRA) further enhances changes in single kidney blood flow and restoration of kidney function, as well as to assess the relationship between MSC dose and measures of kidney function.

Full Title of Study: “Hypoxia and Inflammatory Injury in Human Renovascular Hypertension : Phase 1 Trial of Mesenchymal Stem Cell Therapy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 25, 2020

Detailed Description

These studies include participation by human subjects using a 3-day inpatient CRU protocol at St. Mary's Hospital. Studies include formal measurement of blood and urinary markers of kidney function, BOLD MR and multidetector CT scanning. Forty-two non-diabetic patients between 40 and 80 years of any race or ethnicity will be recruited. All will have hypertension (defined as BP≥140/90 mmHg or ongoing antihypertensive drug therapy) but will have less than 180 mmHg to be included (with or without drug therapy). These subjects will be free of cardiovascular events within 3 months and will not have implanted electrical devices, such as a pacemaker or defibrillator. All patients will have identified large vessel renovascular disease (RVD) for Aims 1, 2 and 3. At least 10% of these subjects will be of African-American descent (self-identified) and recruited in collaboration with the University of Mississippi under the direction of Dr. Luis Juncos and the University of Alabama under the direction of Dr. David Calhoun. For completion of Aims 2 and 3, a three-day evaluation will be repeated between three and four months later, and ongoing safety and imaging studies will be performed up to 24 months after MSC administration. Participants in these protocols will undergo transvenous kidney biopsy under the direction of Drs. McKusick and Misra and their colleagues in Interventional Radiology. All subjects for these studies will complete the research plan at Mayo Clinic, Rochester, Minnesota.

Interventions

  • Drug: Mesenchymal stem cell
    • Intra-arterial infusion of the single-dose MSC
  • Procedure: Mesenchymal stem cell delivery with stent placement
    • Intra-arterial stent placement after Mesenchymal stem cell infusion

Arms, Groups and Cohorts

  • Active Comparator: Mesenchymal stem cell delivery
    • To determine hemodynamic and immunologic changes associated with intra-renal delivery of adipose-derived MSC into human subjects with advanced RVD.
  • Active Comparator: Mesenchymal stem cell delivery with stent placement
    • To test adjunctive delivery of MSC to individuals with advanced RVD undergoing renal artery stenting.

Clinical Trial Outcome Measures

Primary Measures

  • Change in Kidney function
    • Time Frame: 3 months
    • Renal Tissue oxygenation
  • Safety of Mesenchymal stem cell infusion
    • Time Frame: 2 years
    • Number of patients with tissue injury markers

Secondary Measures

  • Decrease in Kidney inflammation
    • Time Frame: 3 months
    • Venous and tissue biomarkers of inflammation

Participating in This Clinical Trial

Inclusion Criteria

  • Creatinine <2.2 mg/dL for Caucasian males, <2.0 Caucasian females,< 2.4 African-American males, <2.1 mg/dL African-American females – Hypertension (Systolic BP>155 mm Hg) and/or requirement for two or more antihypertensive medications: no restrictions on antihypertensive agents, although loop diuretics will be changed to diluting site agents (e.g. hydrochlorothiazide, indapamide, metolazone) prior to study. – Angiotensin Converting Enzyme (ACE inhibitor) or Angiotensin Receptor Blocker (ARB) therapy maintained or initiated at usual recommended daily dose (equivalent: 40 mg lisinopril) . Exclusion Criteria:

  • Diabetes requiring insulin or oral hypoglycemic medications (see text) – Known allergy to furosemide or iodinated intravenous contrast – Pregnancy – Recent Cardiovascular event: Myocardial infarction, stroke, congestive heart failure within 3 months – Cardiac ejection fraction less than 30% – Evidence of hepatitis B or C, or HIV infection – requirement for potentially nephrotoxic drugs, e.g. non-steroidal anti-inflammatory drugs – Uncontrolled hypertension: SBP >180 mm Hg, despite antihypertensive therapy – Kidney transplant – Pacemaker, implantable defibrillator or other contraindication to Magnetic resonance imaging – Inability to comply with breath-hold for 30 seconds – History of deep venous thrombosis within 3 months of enrollment – contraindications to renal biopsy including artificial valve requiring continuous anticoagulation

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Mayo Clinic
  • Collaborator
    • University of Mississippi Medical Center
  • Provider of Information About this Clinical Study
    • Principal Investigator: Stephen C. Textor, M.D., PI – Mayo Clinic
  • Overall Official(s)
    • Stephen C Textor, M.D., Principal Investigator, Mayo Clinic

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.